Trial
NCT02686008
Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC
Phase IWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Yale University
Collaborators
—
Condition
Squamous Cell Carcinoma of the Head and Neck
Intervention
Olaparib
Why stopped
The study was stopped due to lack of funding.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-13